^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Muscarinic receptor antagonist

    Related drugs:
    2d
    Representation of Spatiotemporal Information in Human Episodic Memory and Navigation (clinicaltrials.gov)
    P1, N=15, Enrolling by invitation, University of Arizona
    New P1 trial
    2d
    OSCIVARI: Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient (clinicaltrials.gov)
    P2, N=4, Terminated, University Hospital, Lille | N=35 --> 4 | Recruiting --> Terminated; Following Brexit and the unavailability of the experimental drug (PT003) in France, the study was terminated prematurely.
    Enrollment change • Trial termination
    2d
    Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy (clinicaltrials.gov)
    P4, N=93, Not yet recruiting, Iuliu Hatieganu University of Medicine and Pharmacy
    New P4 trial
    5d
    Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation (clinicaltrials.gov)
    P=N/A, N=3598, Completed, AstraZeneca
    New trial • Real-world evidence
    9d
    VENTURI (VENTilation Using Respiratory Imaging) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    10d
    RETRIBUTE: Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients (clinicaltrials.gov)
    P=N/A, N=396, Not yet recruiting, Chiesi Farmaceutica Ltda.
    New trial • Real-world evidence
    16d
    Effect of Ipratropium Bromide on EILO (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Cook Children's Health Care System
    New P2 trial
    19d
    Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography (clinicaltrials.gov)
    P=N/A, N=102, Recruiting, Cairo University
    New trial
    20d
    4-Chlorobenzylamine Containing Maleic Acid Derivatives: Synthesis, In Silico Studies, and Anti-Alzheimer's Activity. (PubMed, ACS Chem Neurosci)
    The goal of this investigation was to see if new maleic acid derivatives could protect the brain from scopolamine-induced amnesia...The observation from the MWM model showed a decrease in the escape latency time in the rats. Finally, the AutoDock Vina program was used to check ligand-protein interaction using COX-2, and TNF-α, JNK, NFκB, GSK-3β, and ACE were used as targets.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    22d
    Dose-dependent effects of vildagliptin (DPP-4 inhibitor) in a scopolamine-induced memory impairment model in rats. (PubMed, Life Sci)
    These findings suggest that vildagliptin may exert protective effects against cognitive impairment by modulating cholinergic activity, inflammatory responses, and lipid peroxidation.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    23d
    Early intervention in patients with mild to moderate chronic obstructive pulmonary disease (ChiCTR2500113245)
    P4, N=1070, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University
    New P4 trial
    23d
    TRITON: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (clinicaltrials.gov)
    P3, N=3433, Completed, Chiesi Farmaceutici S.p.A. | Active, not recruiting --> Completed
    Trial completion